Helicobacter pylori infection: diagnosis and treatment

References

• P, Smith PD (Eds), Lippincott—Raven, PA, USA, 1–14 (1997).
   Google Scholar
• •Good review of the epidemiology of Helicobacter pylori infections.
   Google Scholar
• Nurgalieva ZZ, Malaty HM, Graham DY, et al Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am. J Top. Med Hyg 67(2), 201–206 (2002).
   Google Scholar
• Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemial Rev. 22(2), 283–297 (2000).
   Google Scholar
• Tytgat GN. Endoscopic transmission of Helicobacter pylori. Aliment. Pharmacol Ther 9\(Suppl. 2), 105–110 (1995).
   Google Scholar
• Wu MS, Wang JT, Yang JC, et al Effective reduction of Helicobacter pylori infection after upper gastrointestinal endoscopy by mechanical washing of the endoscope. Hepatogastroenterology 43(12), 1660–1664 (1996).
   Google Scholar
• Malaty HM, Graham DY, Klein PD, Evans DG, Adam E, Evans DJ. Transmission of Helicobacter pylori infection. Studies in families of healthy individuals. Scand Gastroenterd 26(9), 927–932 (1991). Demonstrates intrafamily infection.
   Google Scholar
• Malaty HM, Tanaka E, Kumagai T, et al Seroepidemiology of Helicobacter pylori and hepatitis A virus and the mode of transmission of infection: a 9-year cohort study in rural Japan. Clin. Infect. Dis. 37(8), 1067–1072 (2003).
   Google Scholar
• Perez-Perez GI, Witkin SS, Decker MD, Blaser MJ. Seroprevalence of Helicobacter pylori infection in couples. J Clin. Microbial 29(3), 642–644 (1991).
   Google Scholar
• Veldhuyzen van Zanten SJ. Do socio-economic status, marital status and occupation influence the prevalence of Helicobacter pylori infection? Aliment. Pharmacol Ther 9\(Suppl. 2), 41–44 (1995).
   Google Scholar
• Malaty HM, Evans DJ Jr, Abramovitch K, Evans DG, Graham DY. Helicobacter pylori infection in dental workers: a seroepidemiology study. Am. J. Gastroenterol 87(12), 1728–1731 (1992).
   Google Scholar
• Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J. Infect. Dis. 181(4), 1359–1363 (2000).
   Google Scholar
• Graham DY. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology 113(6 Suppl.), S113—S117 (1997).
   Google Scholar
• Axon A, Forman D. Helicobacter gastroduodenitis: a serious infectious disease. Br. Med. j 314(7092), 1430–1431 (1997). Discusses the fact that H. pylori infection is never trivial or helpful.
   Google Scholar
• Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer andgastric cancer: a model. Gastroenterology 113(6), 1983–1991 (1997).
   Google Scholar
• Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J. Gastroenterol 35\(Suppl. 12), 90–97 (2000). Discusses the role of H. pylon i in gastric cancer.
   Google Scholar
• Shiotani A, Graham DY. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin. North Am. 86(6), 1447–1466 (2002).
   PubMedGoogle Scholar
• Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am. J Gastroenterol 98(7), 1462–1470 (2003).
   PubMedGoogle Scholar
• Uemura N, Okamoto S, Yamamoto S, et al.Helicobacter pylori infection and the development of gastric cancer. N Engl J. Med. 345(11), 784–789 (2001). Eradication of H. pylon i is likely to reduce the incidence of gastric cancer.
   Google Scholar
• Graham DY. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem. Am. J.Gastroenterol 89(4), 469–472 (1994).
   Google Scholar
• Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht 2–2000 Consensus Report. Aliment. Pharmacol Ther 16(2), 167–180 (2002). Consensus conference results regarding diagnosis and therapy.
   Google Scholar
• Graham KS, Graham DY. Contemporarydiagnosis and management ofH. pylon-associated gastrointestinal diseases. Handbooks in Healthcare Co., PA, USA (1998).
   Google Scholar
• Mobley HLT, Mendz GL, Hazell SL (Eds), ASM Press, Washington, DC, USA (2001).
   Google Scholar
• Miehlke S, Bayerdorffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin. Gastrointest. Dis. 12(3), 167–179 (2001).
   Google Scholar
• Graham DY, Klein PD. Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. Gastroenterol Clin. North Am. 29(4), 885–893 (2000).
   Google Scholar
• El-Zimaity HM, Segura AM, Genta RI\4, Graham DY. Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik and Genta stains. Mod. Pathol 11(3), 288–291 (1998).
   Google Scholar
• Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115(5), 1272–1277 (1998).
   Google Scholar
• Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol Ther. 18(6), 647–654 (2003).
   Google Scholar
• •Meta-analysis showing that differentproton pump inhibitors provide comparable results for the eradication of H. pylori.
   Google Scholar
• Gold BD, Colletti RB, Abbott M, et al.Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J. Pediatr. Gastroenterol Nutr. 31(5), 490–497 (2000).
   Google Scholar
• Chiba N, Rao BY, Rademaker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am. J. Gastroenterol 87(12), 1716–1727 (1992).
   Google Scholar
• Berstad A, Berstad K, Wilhelmsen I, Hatlebakk JG, Nesje LB, Hausken T Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Aliment. Pharmacol Ther. 9(2), 197–200 (1995).
   Google Scholar
• Taylor DE. Pathophysiology of antibiotic resistance: clarithromycin. Can. J. Gastroenterol 14(10), 891–894 (2000).
   PubMedGoogle Scholar
• Dore MP, Leandro G, ReaMi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 45(1), 68–76 (2000).
   Google Scholar
• Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J. Antimicrob. Chemother 50(6), 849–856 (2002).
   Google Scholar
• Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the USA. Arch. Intern. Med. 161(9), 1217–1220 (2001).
   Google Scholar
• Thyagarajan SP, Ray P, Das BK, et al Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: multicentric study. J. Gastroenterol Hepatol 18(12), 1373–1378 (2003).
   Google Scholar
• Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol 94(7), 1751–1759 (1999).
   Google Scholar
• Gerrits MM, Beming M, van Vliet AH, Kuipers EJ, Kusters JG. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47(9), 2984–2986 (2003).
   PubMedGoogle Scholar
• Kwon DH, Kim JJ, Lee M, et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 44(11), 3203–3205 (2000).
   Google Scholar
• Liu WZ, Xiao SD, Shi Y, et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment. Pharmacol Then. 13(3), 317–322 (1999).
   Google Scholar
• Segura AM, Gutierrez O, Otero W, Angel A, Genta RI\4, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment. Pharmacol Ther 11(3), 529–532 (1997).
   Google Scholar
• Leung WK, Graham DY. Rescue therapy for Helicobacter pylori. Curr. Treat. Options Gastroenterol 5(2), 133–138 (2002).
   PubMedGoogle Scholar
• •Review of approaches to rescue therapy fortreatment failures.
   Google Scholar
• Shiotani A, Nurgalieva ZZ, Yamaoka Y, Graham DY. Helicobacter pylori. Med Clin.North Am. 84(5), 1125–1136 (2000).
   PubMedGoogle Scholar
• Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 8(2), 90–94 (2003).
   PubMed Web of Science ®Google Scholar
• Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39(1), 107–111 (1995).
   Google Scholar
• Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47(12), 3942–3944 (2003).
   Google Scholar
• Kagaya H, Kato M, Komatsu Y, et al. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment. Pharmacol. Ther. 14(11), 1523–1527 (2000).
   Google Scholar
• Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin. North Am. 29(4), 819–827 (2000).
   Google Scholar
• Wong BC, Lam SK, Wong WIVI, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. J. Am. Med. Assoc. 291(2), 187–194 (2004).
   Google Scholar
• Leal-Herrera Y, Torres J, Monath TP, et al. High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection. Am. J. Gastroenterol 98(11), 2395–2402 (2003).
   Google Scholar
• •Demonstrates that reinfection is commonin developing countries with poor general sanitation.
   Google Scholar
• Soto G, Bautista CT, Roth DE, et al.Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J. Infect. Dis. 188(9), 1263–1275 (2003).
   Google Scholar
• Graham DY. Therapy of Helicobacterpylori: current status and issues. Gastroenterology 118(2 Suppl. 1), S2—S8 (2000).
   Google Scholar
• Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment. Pharmacol. Then 18(8), 757–766 (2003).
   Google Scholar
• Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection — a meta-analysis. Aliment. Pharmacol. Then 13(7), 857–864 (1999).
   Google Scholar
• Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Then 17(1), 99–109 (2003).
   Google Scholar
• •Outcome of therapy in clinical practice isfar lower than predicted in pharmaceutical supported trials.
   Google Scholar
• Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int. J. Epidemiol 31(1), 128–139 (2002).
   Google Scholar
• Moayyedi P, Feltbower R, Crocombe W, et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment. Pharmacol. Ther. 14(6), 719–728 (2000).
   Google Scholar
• •Outcome of therapy in clinical practice is far lower than predicted in pharmaceutical supported trials.
   Google Scholar
• Della MR, Lavagna A, Masoero G, Lombardo L, CroceIla L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment. Pharmacol. Ther. 16 (7),1269-1275 (2002).
   Google Scholar
• •Outcome of therapy in clinical practiceis far lower than predicted in pharmaceutical supported trials.
   Google Scholar
• Boixeda D, Martin dA, Bermejo F, Lopez SA, Hernandez RF, Garcia PA. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. Factors that influence Helicobacter pylori eradications success. Rev. Esp. Enfirm. Dig. 95(3), 206–209 (2003).
   Google Scholar
• Ellenrieder V, Fensterer H, Waurick M, Adler G, Glasbrenner B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment.Pharmacol. Ther. 12(7), 613–618 (1998).
   PubMedGoogle Scholar
• Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment. Pharmacol. Ther. 13(6), 719–729 (1999).
   Google Scholar
• Graham DY, Hammoud F, El Zimaity HM, Kim JG, Osato MS, El Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment. Pharmacol Then 17(10), 1229–1236 (2003).
   Google Scholar
• Miwa H, Nagahara A, Kurosawa A, et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment. Pharmacol. Ther 17(12), 1545–1551 (2003).
   Google Scholar
• McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann. Intern. Med. 139(6), 463–469 (2003).
   Google Scholar
• Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol Ther 17(11), 1333–13430 (2003).
   Google Scholar
• Graham DY, Osato MS, Hoffman J, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment. Pharmacol Ther 14(6), 745–750 (2000).
   Google Scholar
• Graham DY, Dore MR The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology 125(2), 639 (2003).
   PubMedGoogle Scholar
• Buring SM, Winner LH, Hatton RC, Doering PL. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 19(3), 324–332 (1999).
   Google Scholar
• Crone J, Granditsch G, Huber WD, et al.Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997–2000. J. Pediatr. Gastroenterol Nutr 36(3), 368–371 (2003).
   Google Scholar
• Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment. Pharmacol Ther. 18(6), 627–633 (2003).
   Google Scholar
• Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment. Pharmacol Ther. 17(4), 553–560 (2003).
   Google Scholar
• Cats A, Kuipers EJ, Bosschaert MA, et al Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment. Pharmacol Ther 17(3), 429–435 (2003).
   Google Scholar
• Graham DY, Anderson SY, Lang T. Garlic or jalapeno peppers for treatment of Helicobacter pylori infection. Am. J. Gastroenterol 94(5), 1200–1202 (1999).
   Google Scholar
• Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22(4), 360–366 (2003).
   Google Scholar
• Sherman P, Hassall E, Hunt RH, Fallone CA, Veldhuyzen van Zanten S, Thomson AB. Canadian Helicobacter study group consensus conference on the approach to Helicobacter pylori infection in children and adolescents. Can. J. Gastroenterd 13(7), 553–559 (1999).
   Google Scholar
• Drumm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. J. Pediatr Gastroenterd Nutr 30(2),207-213 (2000).
   Google Scholar
• Kostaki M, Fessatou S, Karpathios T Refractory iron-deficiency anaemia due to silent Helicobacter pylori gastritis in children. Eur j Pediatr 162(3), 177–179 (2003).
   Google Scholar
• Vallve M, Vergara M, Gisbert JP, Calvet X Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment. Pharmacol Ther 16(6), 1149–1156 (2002).
   Google Scholar
• Hassan C, De Francesco V, Zullo A, et al Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment. Pharmacol Ther 18(6), 641–646 (2003).
   Google Scholar
• •Introduction to sequential therapy.
   Google Scholar
• Frenck RW Jr, Clemens J. Helicobacter in the developing world. Microbes Infect. 5(8), 705–713 (2003).
   Google Scholar
• Ruggiero E Peppoloni S, Rappuoli R, Del Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect. 5(8), 749–756 (2003).
   Google Scholar